Abstract:

Objective To explore the efficacy and safety of single therapy with antiplatelet in patients with high bleeding risk after PCI. Methods 156 patients with high bleeding risk after PCI，who had been diagnosed and treated in our hospital from May 2016 to May 2018，were selected. According to the antiplatelet therapy regimen，they were divided into aspirin（ASA）+ clopidogrel（CLO）group（24 patients），ASPL + ticagrelor（TIG） group（26 patients），ASA monotherapy group（30 patients），CLO monotherapy group（35 patients），and TIG monotherapy group（41patients）. All the patients were follow up for 1 year and were detected platelet aggregation rate and recorded serious cardiac events，cardiovascular deaths，and BARC 3 or 5 bleeding events. Results ADP⁃ induced platelet aggregation rate was significantly higher in ASA monotherapy than in the other groups（P < 0.05）， and it was markedly lower in ASA + CLO group and TIG group monotherapy（P < 0.05）. Platelet aggregation rate induced by arachidonic acid was significant higher in CLO monotherapy group than in the other groups（P < 0.05）， and there were no significant differences among the other groups（P > 0.05）. The incidence of bleeding events was significantly lower in TIG or CLO monotherapy group than in the other three groups（P < 0.05）. The cardiovascular events in TIG monotherapy group were lower than those in CLO monotherapy group（P < 0.05）. Cardiovascular mortality in TIG monotherapy or ASA + TIG group was lower，and was significantly lower than that in ASA or CLO monotherapy group（P < 0.05）. Conclusions For patients with high bleeding risk，ticagrelormonotherapy does not increase major bleeding while reduces the incidence of cardiovascular events and deaths.

Key words: